Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India

Authors

  • Ravikirti Additional Professor and Head, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
  • Ranjini Roy Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
  • Chandrima Pattadar Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
  • Rishav Raj Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
  • Neeraj Agarwal Professor and Head, Department of Community and Family Medicine, All India Institute of Medical Sciences, Bibinagar, Telangana, India
  • Bijit Biswas Senior Resident, Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India https://orcid.org/0000-0002-7609-6446
  • Pramod Kumar Manjhi Assistant Professor and Head, Department of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India
  • Deependra Kumar Rai Additional Professor and Head, Department of Pulmonary Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
  • Shyama Assistant Professor, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
  • Anjani Kumar Assistant Professor, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
  • Asim Sarfaraz Assistant Professor, Department of Microbiology, All India Institute of Medical Sciences, Patna, Bihar, India

DOI:

https://doi.org/10.18433/jpps32105

Abstract

Background: There has been a growing interest in ivermectin ever since it was reported to have an in-vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This trial was conducted to test the efficacy of ivermectin in mild and moderate coronavirus disease 19 (COVID-19). Methods: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020.  On day 1 and 2 post enrolment, patients in the intervention arm received ivermectin 12 mg while the patients in the non-interventional arm received placebo tablets. Results: About one-fourth (23.6%) of the patients in the intervention arm and one-third (31.6%) in the placebo arm were tested reverse transcriptase polymerase chain reaction (RTPCR) negative for SARS-CoV-2 on 6th day. Although this difference was found to be statistically insignificant [rate ratio (RR): 0.8; 95% confidence interval (CI): 0.4-1.4; p=0.348]. All patients in the ivermectin group were successfully discharged. In comparison the same for the placebo group was observed to be 93%. This difference was found to be statistically significant (RR: 1.1; 95% CI; 1.0-1.2; p=0.045). Conclusions: Inclusion of ivermectin in treatment regimen of mild to moderate COVID-19 patients could not be said with certainty based on our study results as it had shown only marginal benefit in successful discharge from the hospital with no other observed benefits.

Downloads

Download data is not yet available.

Author Biographies

Ravikirti, Additional Professor and Head, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Additional Professor and Head, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Ranjini Roy, Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Chandrima Pattadar, Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Rishav Raj, Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Neeraj Agarwal, Professor and Head, Department of Community and Family Medicine, All India Institute of Medical Sciences, Bibinagar, Telangana, India

Professor and Head, Department of Community and Family Medicine, All India Institute of Medical Sciences, Bibinagar, Telangana, India

Bijit Biswas, Senior Resident, Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Senior Resident, Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Pramod Kumar Manjhi, Assistant Professor and Head, Department of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India

Assistant Professor and Head, Department of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India

Deependra Kumar Rai, Additional Professor and Head, Department of Pulmonary Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Additional Professor and Head, Department of Pulmonary Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Shyama, Assistant Professor, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Assistant Professor, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Anjani Kumar, Assistant Professor, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Assistant Professor, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India

Asim Sarfaraz, Assistant Professor, Department of Microbiology, All India Institute of Medical Sciences, Patna, Bihar, India

Assistant Professor, Department of Microbiology, All India Institute of Medical Sciences, Patna, Bihar, India

Downloads

Published

2021-07-15

How to Cite

Ravikirti, Roy, R., Pattadar, C., Raj, R., Agarwal, N., Biswas, B., Manjhi, P. K., Rai, D. K., Shyama, Kumar, A., & Sarfaraz, A. (2021). Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India. Journal of Pharmacy &Amp; Pharmaceutical Sciences, 24(3), 343–350. https://doi.org/10.18433/jpps32105

Issue

Section

Clinical Pharmacology and Therapeutics